CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 42 enrolled
Drug / intervention
C213 Microneedle System +1 moredrug
Likely dose
Zolmitriptan-coated titanium microneedle array (3 cm² array) attached to 5 cm² adhesive patch via C213 SystemAI-extracted
Key inclusion· 6
  • Age 18–65 years
  • >1 year history of episodic or chronic cluster headache with onset before age 50, meeting ICHD-3 diagnostic criteria including ≥5 attacks of severe unilateral orbital/supraorbital/temporal pain lasting 45–180 min, with ipsilateral autonomic symptoms or restlessness, and frequency of 1 every other day to 8/day for >50% of active period
  • Cluster history in past 12 months: ≥1 cluster period averaging 2–6 headaches/day lasting ≥7 days
  • Able to distinguish cluster headaches from other headache types (migraine, tension-type)
Key exclusion· 17
  • Contraindications to triptans
  • History of hemiplegic migraine or migraine with brainstem aura
  • Participation in another investigational trial within 30 days or 5 half-lives of investigational product (whichever is longer)
  • Previous M207/C213 exposure in a clinical trial

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04066023
NCT04066023Phase 3Completed

Randomized, Double-Blind, Multi-Center, Parallel-Group Comparison of the Efficacy and Safety of the C213 (Zolmitriptan Microneedle System) to Placebo for the Acute Treatment of Cluster Headaches

Zosano Pharma Corporation·interventional·Posted Aug 22, 2019·Updated Jun 14, 2022

In Brief

A Phase 3 clinical trial evaluating C213 Microneedle System and Placebo for Cluster Headache. Completed, enrolled 42 participants across 12 sites.

Detailed Summary

This is a double-blind, placebo-controlled study. Subjects who meet the entry criteria will be randomized o receive one of three blinded treatments \[C213 1.9 mg patch and placebo patch; C213 3.8 mg (1.9 mg x 2 patches), two placebo patches\] on Day 1 and will have up to 48 weeks to confirm and treat a cluster headache. Subjects will self-administer the patches and respond to questions in the electronic diary (eDiary) until 1-hour post treatment administration.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
Collaborators--

Timeline

Phase 3CompletedFinished
2020202120222023202420252026
First PostedAug 22, 2019
Enrollment StartOct 3, 2019
Primary CompletionApr 14, 2021
TodayJul 2, 2026
Enrollment to primary: 1.5 yearsPosted 6.9 years ago

Interventions

C213 Microneedle Systemdrug

The C213 System is a proprietary disposable patch and a reusable applicator. The zolmitriptan-coated titanium microneedle array (3 cm\^2 array) is attached to a 5 cm\^2 adhesive patch.

Placebodrug

The C213 System is a proprietary disposable patch and a reusable applicator. The placebo patch is a single use, 3 cm\^2 Placebo (intracutaneous microneedle) system that contains no active ingredients.